Fig. 2: PD-1 RNA expression amongst diverse cancers.
From: PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome
A PD-1 expression by RNA sequencing was measured as a percentile rank, with ≥75 considered ‘high’ (yellow), 25–74 as ‘intermediate’ (blue) and <25 considered ‘low’ (green), based on comparison to a reference population of 735 tumors and normalized to a value of 1–100. B PD-1 RNA expression in 10,071 TCGA cancers (as z-scores relative to all samples) is generated in cBioPortal for Cancer Genomics. Median PD-1 expression, indicated by the solid red line, is ranked from low to high (left to right), with adrenocortical carcinoma having lowest median PD-1 expression and seminoma having highest median PD-1 expression. Abbreviations: TCGA The Cancer Genome Atlas, ACC Adrenocortical Carcinoma, O. melanoma Ocular melanoma, NSGCT Non-Seminomatous Germ Cell Tumo, Misc. NET Miscellaneous Neuroepithelial Tumor, Pheochromo. Pheochromocytoma, Renal non-CC renal non-clear cell, Pleural mesoth. Pleural Mesothelioma, H&N cancer Head & Neck cancer, Ovarian epith. Ovarian Epithelial Tumor, Endom. Cancer Endometrial Cancer, Panc. Cancer Pancreatic Cancer, NSCLC Non-Small Cell Lung Cancer, TET Thymic Epithelial Tumor.
